UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors

CPT: pharmacometrics and systems pharmacology, 2021-05, Vol.10 (5), p.455-466

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Enzyme Inhibition on Perampanel Pharmacokinetics: Why Study Design Matters

Epilepsy research, 2017-08, Vol.134, p.41-48

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

Clinical and translational science, 2018-09, Vol.11 (5), p.477-486

2018

Link zum Volltext

Verfügbarkeit prüfen

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.777-791

2019

Link zum Volltext

Verfügbarkeit prüfen

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

CPT: pharmacometrics and systems pharmacology, 2023-04, Vol.12 (4), p.444-461

2023

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges

CPT: pharmacometrics and systems pharmacology, 2020-01, Vol.9 (1), p.5-20

2020

Link zum Volltext

Verfügbarkeit prüfen

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

CPT: pharmacometrics and systems pharmacology, 2018-03, Vol.7 (3), p.135-146

2018

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

CPT: pharmacometrics and systems pharmacology, 2019-09, Vol.8 (9), p.685-695

2019

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

International journal of pharmaceutics, 2013-02, Vol.443 (1-2), p.9-16

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents

Expert review of anti-infective therapy, 2005-06, Vol.3 (3), p.361-373

2005

Link zum Volltext

Verfügbarkeit prüfen

Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model

Bioorganic & medicinal chemistry letters, 2011-03, Vol.21 (6), p.1639-1643

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.229-237

2012

Link zum Volltext

Verfügbarkeit prüfen

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

The Lancet infectious diseases, 2021-08, Vol.21 (8), p.1129-1140

2021

Link zum Volltext

Verfügbarkeit prüfen

Perampanel and pregnancy

Epilepsia (Copenhagen), 2021-03, Vol.62 (3), p.698-708

2021

Link zum Volltext

Verfügbarkeit prüfen

Changes in perampanel levels during de‐induction: Simulations following carbamazepine discontinuation

Acta neurologica Scandinavica, 2020-08, Vol.142 (2), p.131-138

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers

Journal of clinical pharmacology, 2005-07, Vol.45 (7), p.822-831

2005

Link zum Volltext

Verfügbarkeit prüfen

Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers

Antimicrobial agents and chemotherapy, 2021-03, Vol.65 (4)

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial

Alzheimer disease and associated disorders, 2022-07, Vol.36 (3), p.200

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

British journal of clinical pharmacology, 2018-05, Vol.84 (5), p.952-960

2018

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase

Journal of medicinal chemistry, 2014-03, Vol.57 (6), p.2582-2588

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4543: Characterization of the liposomal formulation of eribulin mesylate (E7389) in mice

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4543-4543

2015

Link zum Volltext

Verfügbarkeit prüfen

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P289-P289

2018

Link zum Volltext

Verfügbarkeit prüfen

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_5), p.P289-P289

2018

Link zum Volltext

Verfügbarkeit prüfen

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_30)

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(44)
Dissertationen
(1)

Sprache

Englisch
(45)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors

Effect of Enzyme Inhibition on Perampanel Pharmacokinetics: Why Study Design Matters

Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents

Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model

Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

Perampanel and pregnancy

Changes in perampanel levels during de‐induction: Simulations following carbamazepine discontinuation

Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers

Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase

Abstract 4543: Characterization of the liposomal formulation of eribulin mesylate (E7389) in mice

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Suchergebnisse filtern